Tumor Associated Lymph node T cell is named as a drug or biological intervention in 2 clinical trials in our China trial register, 2 of which are recruiting. The lead sponsor is Guangzhou FineImmune Biotechnology Co., LTD.. Registered phase: Phase 1. Conditions studied include Advanced Solid Tumor; Tumor Associated Lymph Node T Cell; Immunotherapy.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06302062 | Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy |
Phase 1 | Recruiting |
| NCT06716619 | A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors (ClinicalTrials.gov ↗) Tumor Associated Lymph Node T Cell, Advanced Solid Tumor, Immunotherapy |
Phase 1 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Advanced Solid Tumor | 2 |
| Tumor Associated Lymph Node T Cell | 2 |
| Immunotherapy | 2 |
| Serplulimab Injection | 1 |
| Lead sponsor | Trials |
|---|---|
| Guangzhou FineImmune Biotechnology Co., LTD. | 2 |
| Register | Tumor Associated Lymph node T cell trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tumor Associated Lymph node T cell works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tumor Associated Lymph node T cell (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.